Assistant Professor, Medicine, University of Washington School of Medicine
Hematology
Dr. Roland B. Walter, MD
|
|
Give Review
Dr. Roland B. Walter works in the field of Hematology. Roland Walter is also a published doctor. He has 100 paper published. The most recent paper is: Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Roland B. Walter, MD accepts Medicare.
Publications
- Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?
- Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: ...
- Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with Acute myeloid leukaemia or high-risk MDS.
- Evidence-based focused review of primary antifungal prophylaxis during curative-intent therapy for Acute myeloid leukemia.
- Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia.
- Effect of genetic profiling on prediction of therapeutic resistance and survival in adult Acute myeloid leukemia.
- Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in Acute myeloid leukemia.
- Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center.
- Low platelet count reduces subsequent complete remission rate despite marrow With <5% blasts after AML induction therapy.
- Evidence-based focused review of minimal residual disease-directed therapy in Acute myeloid leukemia.
- Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with Acute myeloid leukemia.
- The Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy.
- G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of Acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloprolif...
- Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for AML in First Morphological Remission.
- Value of Routine 'Day 14' Marrow Exam in Newly-Diagnosed AML.
- The role of CD33 as therapeutic target in Acute myeloid leukemia.
- Factors associated with early reinduction chemotherapy for adults with Acute myeloid leukemia.
- Management of older or unfit patients with Acute myeloid leukemia.
- Comparison of minimal residual Disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hemato...
- The past and future of CD33 as therapeutic target in Acute myeloid leukemia.
- High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric Acute myeloid leukemia: a report from the Children's Oncology Group.
- Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human Acute myeloid leukemia.
- Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health Initiative.
- Biting back: BiTE antibodies as a promising therapy for Acute myeloid leukemia.
- Rapid rate of peripheral blood blast clearance accurately predicts complete remission in Acute myeloid leukemia.
- Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated Acute myeloid leukemia patients: North American Intergroup Phase II study SWOG ...
- Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in Acute myeloid leukemia.
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia.
- Prediction of adverse events during Intensive Induction chemotherapy for Acute myeloid leukemia or high-grade myelodysplastic syndromes.
- Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory Acute myeloid l...
- Chronic Myeloid Leukemia in Lymphoid Blast Crisis.
- Outpatient management following intensive induction or salvage chemotherapy for Acute myeloid leukemia.
- CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in Acute myeloid leukemia.
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.
- Associations between allergies and risk of Hematologic malignancies:Results from the VITamins and lifestyle (VITAL) cohort study.
- A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed Acute myeloid leukaemia.
- Significance of minimal residual Disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
- Regular recreational physical activity and risk of Hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study.
- Significance of expression of ITGA5 and its splice variants in Acute myeloid leukemia: A report from the Children's Oncology Group.
- A phase III study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with Acute myeloid leukemia.
- Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Contai...
- AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin.
- Significance of FAB subclassification of "Acute Myeloid Leukemia, NOS" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients.
- Mott Cells.
- Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in Acute leukemia.
- High expression of neutrophil elastase predicts improved survival in pediatric Acute myeloid leukemia: a report from the Children's Oncology Group.
- Phase 2 trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated Acute myeloid leukemia.
- Cancer risk Associated with long-term use of acetaminophen in the prospective VITamins And Lifestyle (VITAL) study.
- Prediction of early death after induction therapy for newly diagnosed Acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.
- Vitamin, mineral, and specialty supplements and risk of Hematologic malignancies in the prospective VITamins And Lifestyle (VITAL) study.
- Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of Hematologic malignancies: results from the prospective Vitamins and...
- Impact of pretransplantation minimal residual Disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation fo...
- Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and Acute myeloid leukemia: a pilot study.
- Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization.
- Shortcomings in the clinical evaluation of new drugs: Acute myeloid leukemia as paradigm.
- High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric Acute myeloid leukemia: a report f...
- Effect of complete remission and responses less than complete remission on survival in Acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest...
- Pretargeted radioimmunotherapy for Hematologic and other malignancies.
- Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against Acute myeloid leukemia (AML) cells ...
- ITIM-dependent endocytosis of CD33-related Siglecs: role of intraCellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2.
- CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with Acute myeloid leukemia treated with gemtuzuma...
- Functional expression of the CD163 scavenger receptor on Acute myeloid leukemia cells of monocytic lineage.
- PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize Leukemia and myeloma cells by a pBR-independent, direct transp...
- Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity.
- Functional tetrahydrobiopterin synthesis in human platelets.
- The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML Cells to gemtuzumab ozogamicin.
- Critical role of interleukin-1beta for transcriptional regulation of endothelial 6-pyruvoyltetrahydropterin synthase.
- Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in Acute myeloid leukemia cells.
- Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in Acute myeloid leukemia.
- Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.
- Drotrecogin alfa (activated) for the treatment of meningococcal Purpura fulminans.
- Gemcitabine-associated hemolytic-uremic Syndrome.
- High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric Acute myeloid leukemia: a report from the ...
- The treatment-related mortality score is Associated with non-fatal adverse events following intensive AML induction chemotherapy.
- Adiponectin induces the transforming growth factor decoy receptor BAMBI in human hepatocytes.
- Xiphophorus genetic linkage map: beginnings of comparative gene mapping in fishes.
- A proposed classification scheme for Xiphophorus melanomas based on histopathologic analyses.
- Genetic analysis of susceptibility to spontaneous and UV-induced carcinogenesis in Xiphophorus hybrid fish.
- Images in clinical medicine. Vitiligo and pernicious Anemia.
- Near-fatal arrhythmia caused by hyperkalaemia.
- Acute, life-threatening hypoglycemia associated with haloperidol in a hematopoietic stem cell transplant recipient.
- [Diabetic ketoacidosis and hyperosmolar hyperglycemia. 24 consecutive cases].
- Acute severe anaemia in an elderly patient with hereditary sphaerocytosis.
- Acidosis induced by lactate, pyruvate, or HCl increases blood viscosity.
- Rapid detection of pathogenic fungi from clinical specimens using LightCycler real-time fluorescence PCR.
- Life-threatening thrombocytopenia associated with Acute Epstein-Barr virus infection in an older adult.
- Impairment of blood rheology by cholestatic jaundice in human beings.
- Letter regarding article by Vita et al, "serum myeloperoxidase levels independently predict endothelial dysfunction in humans".
- Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in Acute myeloid leukemia cells.
- Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with Acute myeloid leukemia in first remission.
- Assessment of digital clubbing in medical inpatients by digital photography and computerized analysis.
- Safety of lumbar puncture for adults with Acute leukemia and restrictive prophylactic platelet transfusion.
- Fatal hepatic veno-occlusive disease Associated with terbinafine in a liver transplant recipient.
- Fatal necrotizing fasciitis due to Streptococcus pneumoniae after renal transplantation.
- HMG-CoA reductase inhibitors are Associated with decreased serum neopterin levels in stable coronary artery disease.
- Cutaneous graft-versus-host Disease: a guide for the dermatologist.
- Phosphorylated ITIMs enable ubiquitylation of an inhibitory Cell surface receptor.
- The power of comparative studies.
- Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory Myeloid malignancies.
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Burkitt's Lymphoma
- View All
Doctors Specialties
- Hematology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Choice Health
- Coop Core
- Medicare Advantage PFFS
- HealthSmart
- Medicaid
- Medicare MCR
- Molina
- ODS Health Plan
- Providence Health Plans
- Preferred Provider Network PPN
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Wells Fargo Insurance
Education
-
University of Washington -
University of Zurich Faculty of Medicine
Hospital
-
Seattle Children's Hospital -
University of Washington Medical Center
Drug Facts
| NPI NUMBER | 1124139738 | |
| NPPES Provider LastName | WALTER | |
| NPPES Provider FirstName | ROLAND | |
| NPPES Provider ZIPCode | 981091023 | |
| NPPES Provider State | WA | |
| Specialty Description | Hematology | |
| Total Claim Count | 43.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1124139738 |
| Last Name Of The Provider | WALTER |
| First Name Of The Provider | ROLAND |
| View All |
Similar Doctors
|
|
Dr. Stephen H. Petersdorf, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric M. Feldman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Garcia, MD |
|
|
Dr. Carl A. Blau, MD |
|
|
Dr. Sioban B. Keel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James C. Detter, MD |
|
|
Dr. Harvey A. Greisman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gerald J. Roth, MD |
|
|
Dr. Aisha A. Alkhinji, MD |
|
|
Dr. Aude Chapuis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David Wu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Akshay D. Shah, MD |
|
|
Dr. Maria T. Zudaire, MD |
|
|
Dr. Gottfried Schmer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Stefanie Buchholz |